Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pyxis Oncology (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation antibody-drug conjugate therapeutics, has announced the granting of inducement stock options to four new employees. The company's Compensation Committee approved options to purchase 246,238 shares of common stock under the 2022 Inducement Plan.
The stock options are structured in two tranches: 181,238 options vest over four years with 25% vesting after one year and the remainder monthly over 36 months, while 65,000 options vest fully on December 31, 2025. All options have a ten-year term and an exercise price of $1.10 per share, matching Pyxis Oncology's closing stock price on June 30, 2025.
Pyxis Oncology (Nasdaq: PYXS), un'azienda in fase clinica focalizzata sullo sviluppo di terapie di nuova generazione basate su coniugati anticorpo-farmaco, ha annunciato la concessione di stock option di incentivazione a quattro nuovi dipendenti. Il Comitato per la Retribuzione della societ脿 ha approvato opzioni per l'acquisto di 246.238 azioni ordinarie nell'ambito del Piano di Incentivazione 2022.
Le stock option sono strutturate in due tranche: 181.238 opzioni maturano in quattro anni con il 25% che matura dopo un anno e il resto mensilmente nei successivi 36 mesi, mentre 65.000 opzioni maturano completamente il 31 dicembre 2025. Tutte le opzioni hanno una durata di dieci anni e un prezzo di esercizio di $1,10 per azione, corrispondente al prezzo di chiusura delle azioni di Pyxis Oncology del 30 giugno 2025.
Pyxis Oncology (Nasdaq: PYXS), una empresa en etapa cl铆nica centrada en el desarrollo de terapias conjugadas anticuerpo-f谩rmaco de pr贸xima generaci贸n, ha anunciado la concesi贸n de opciones sobre acciones como incentivo a cuatro nuevos empleados. El Comit茅 de Compensaci贸n de la compa帽铆a aprob贸 opciones para comprar 246,238 acciones ordinarias bajo el Plan de Incentivos 2022.
Las opciones sobre acciones est谩n estructuradas en dos tramos: 181,238 opciones se consolidan en cuatro a帽os con un 25% que se consolida tras un a帽o y el resto mensualmente durante 36 meses, mientras que 65,000 opciones se consolidan completamente el 31 de diciembre de 2025. Todas las opciones tienen un plazo de diez a帽os y un precio de ejercicio de $1.10 por acci贸n, igualando el precio de cierre de las acciones de Pyxis Oncology al 30 de junio de 2025.
Pyxis Oncology (雮橃姢雼�: PYXS)電� 彀劯雽� 頃泊-鞎诫 鞝戫暕 旃橂鞝� 臧滊皽鞐� 欤茧牓頃橂姅 鞛勳儊 雼硠 須岇偓搿�, 雱� 氇呾潣 鞁犾瀰 歆侅洂鞐愱矊 鞙犾澑 鞀ろ啞鞓奠厴鞚� 攵�鞐枅雼り碃 氚滍憸頄堨姷雼堧嫟. 須岇偓鞚� 氤挫儊 鞙勳洂須岆姅 2022雲� 鞙犾澑 瓿勴殟鞐� 霐半澕 246,238欤�鞚� 氤错喌欤� 毵れ垬 鞓奠厴鞚� 鞀轨澑頄堨姷雼堧嫟.
鞀ろ啞鞓奠厴鞚� 霊� 臧滌潣 韸鸽灉旃橂 甑劚霅橃柎 鞛堨姷雼堧嫟: 181,238 鞓奠厴鞚� 4雲勳棎 瓯胳硱 氩犾姢韺呺悩氅� 1雲� 頉� 25%臧� 氩犾姢韺呺悩瓿� 雮橂ǜ歆�電� 36臧滌洈 霃欖晥 毵れ洈 氩犾姢韺呺悩氅�, 65,000 鞓奠厴鞚� 2025雲� 12鞗� 31鞚检棎 鞝勳暋 氩犾姢韺呺惄雼堧嫟. 氇摖 鞓奠厴鞚� 鞙犿毃 旮瓣皠鞚� 10雲�鞚措┌ 頄夓偓 臧�瓴╈潃 欤茧嫻 $1.10搿�, 2025雲� 6鞗� 30鞚� Pyxis Oncology 膦呹皜鞕� 霃欖澕頃╇媹雼�.
Pyxis Oncology (Nasdaq : PYXS), une soci茅t茅 en phase clinique sp茅cialis茅e dans le d茅veloppement de th茅rapeutiques conjugu茅es anticorps-m茅dicament de nouvelle g茅n茅ration, a annonc茅 l'octroi d'options d'achat d'actions incitatives 脿 quatre nouveaux employ茅s. Le comit茅 de r茅mun茅ration de la soci茅t茅 a approuv茅 des options pour l'achat de 246 238 actions ordinaires dans le cadre du plan d'incitation 2022.
Les options d'achat d'actions sont r茅parties en deux tranches : 181 238 options acqui猫rent des droits sur quatre ans, avec 25 % d'acquisition apr猫s un an et le reste mensuellement sur 36 mois, tandis que 65 000 options seront enti猫rement acquises le 31 d茅cembre 2025. Toutes les options ont une dur茅e de dix ans et un prix d'exercice de 1,10 $ par action, correspondant au cours de cl么ture de Pyxis Oncology au 30 juin 2025.
Pyxis Oncology (Nasdaq: PYXS), ein klinisch orientiertes Unternehmen, das sich auf die Entwicklung von Therapeutika der n盲chsten Generation auf Antik枚rper-Wirkstoff-Konjugat-Basis spezialisiert hat, hat die Gew盲hrung von Anreiz-Aktienoptionen an vier neue Mitarbeiter bekannt gegeben. Der Verg眉tungsausschuss des Unternehmens genehmigte Optionen zum Kauf von 246.238 Stammaktien im Rahmen des Inducement-Plans 2022.
Die Aktienoptionen sind in zwei Tranchen strukturiert: 181.238 Optionen werden 眉ber vier Jahre mit 25 % nach einem Jahr und dem Rest monatlich 眉ber 36 Monate vesten, w盲hrend 65.000 Optionen am 31. Dezember 2025 vollst盲ndig vesten. Alle Optionen haben eine Laufzeit von zehn Jahren und einen Aus眉bungspreis von 1,10 $ pro Aktie, entsprechend dem Schlusskurs von Pyxis Oncology am 30. Juni 2025.
- None.
- None.
BOSTON, June 30, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation antibody-drug conjugate (鈥楢DC鈥�) therapeutics for difficult-to-treat cancers, reported today that Pyxis Oncology鈥檚 Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 246,238 shares of Pyxis Oncology鈥檚 common stock to four newly hired employees. The awards were granted under the Pyxis Oncology, Inc. 2022 Inducement Plan (the 鈥楶lan鈥�) with a grant date of June 30, 2025, as an inducement material to the new employee entering employment with Pyxis Oncology, in accordance with Nasdaq Listing Rule 5635(c)(4).
An aggregate of 181,238 stock options vest over four years, with
Pyxis Oncology is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The Company is efficiently building next generation therapeutics that hold the potential for monotherapy and combination indications. Its lead candidate, micvotabart pelidotin (MICVO, formerly PYX-201), has been evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors with a go-forward development focus on treating patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) based on the strength of the HNSCC signal that emerged. Additionally, the Company initiated a Phase 1/2 combination study of MICVO and Merck鈥檚 anti-PD-1 therapy, KEYTRUDA庐聽(pembrolizumab), in patients with R/M HNSCC and other advanced solid tumors.
To learn more, visit聽聽or follow us on聽聽(formerly known as Twitter)聽and聽.
Pyxis Oncology Contact
Pamela Connealy
CFO and COO
FAQ
How many stock options did Pyxis Oncology (PYXS) grant to new employees in June 2025?
What is the exercise price for PYXS stock options granted on June 30, 2025?
What is the vesting schedule for Pyxis Oncology's June 2025 stock option grants?
Under which plan were the PYXS stock options granted?
